Effect of thymidine on activity of trimethoprim and sulphamethoxazole

ANNE STOKES AND R. W. LACEY

From the Department of Bacteriology, North Cambridgeshire Hospital, Wisbech, Cambs, UK

SUMMARY Thymidine at levels as low as 0.05 mg/l reduces the activities of sulphamethoxazole and trimethoprim and their combination in vitro. Using a biological assay procedure, levels of thymidine greater than this were interpreted as being present in urine. The addition of sulphamethoxazole and trimethoprim, singly or in combination, to urine obtained from patients with urinary tract infections showed that all the antibacterial effect towards sensitive organisms was due to the trimethoprim component. It is suggested that trimethoprim should replace the combination co-trimoxazole for the treatment of some lower urinary tract infections, and that laboratory media, if they are to resemble the clinical environment, should contain thymidine.

It has been known for many years that the activity of sulphonamides in vitro is affected by the nature of the medium used. The addition of lysed horse red cells to many media has been shown to enhance the activity of sulphonamides and of trimethoprim. This enhancement is due to the neutralisation of antagonists, which comprise mainly thymidine and, to a lesser extent, thymine; the neutralising capacity of horse red cells is due chiefly to the presence of the enzyme thymidine phosphorylase (Bushby, 1973). Accordingly, in recent years, media for sulphonamide and trimethoprim testing have been developed that contain neither thymine nor thymidine (e.g., Wellcotest agar, Oxoid diagnostic sensitivity (DST) agar, Oxoid Iso-Sensitest agar), and sensitivity testing using these media does not require the addition of lysed horse red cells to show optimum activity of sulphonamides or trimethoprim.

Sensitivity testing with thymidine-free agar has been thought to reflect the clinical environment, because of the lack of free thymidine present in vivo (Garrod and O'Grady, 1971; Then and Angerhn, 1974). However, these data were derived mainly from analysis of uninfected tissues, and evidence has been accumulating recently that thymidine or other antagonists are present in infected tissue at levels sufficiently high to inactivate some of the antibacterial effect of sulphonamides and trimethoprim in vivo. This evidence has come from three types of observation:

1. The activities of sulphonamides and trimethoprim were surprisingly poor in an experimental model of urinary infection where there was little evidence of synergy between the drugs (Anderson et al., 1974).
2. Many authors have isolated from purulent lesions bacteria that possess an absolute requirement for thymine or thymidine (Barker et al., 1972; Lacey and Lewis, 1973; Okubadejo and Maskell, 1973; Tanner and Bullen, 1974; Maskell et al., 1976). Such mutants die rapidly in vitro in the absence of thymine or thymidine (Stacey and Simson, 1965; see below), and the isolation of such mutants indicates that levels of thymine or thymidine are present in these patients in amounts sufficient to support the growth of these defective organisms.
3. Maskell et al. (1976) have presented evidence that thymine or thymine-like compounds are present in urine.

In this paper we have assessed the significance of the presence of thymidine in laboratory sensitivity testing media. We also describe the results of experiments performed with the intention of assessing the implications of the presence of thymidine on the treatment of urinary tract infections.

Methods

DETERMINATION OF MINIMUM INHIBITORY CONCENTRATIONS (MIC) IN AGAR

Sulphamethoxazole and trimethoprim were in-
corporated in doubling dilutions, singly or in combination (in a ratio of 20:1 w/w), into media. Single cell inocula (about 50 bacteria per inoculum) were applied to plates that were then incubated for 20 hours. The end-point was taken as the inhibition of more than 95% of colony forming units. Synergy was defined as the enhancement, by at least fourfold, of the activity of trimethoprim in the presence of sulphamethoxazole.

**MEDIA**

The solid media used were Wellcotest, DST (Oxoid), and Blood Agar Base No. 2 (BAB—Oxoid), with or without the addition of 5% (v/v) lysed human or horse red cells. Thymidine was incorporated, generally in doubling dilutions, into some of the media at final levels of between 0-01 and 50 mg/l. Fluid media consisted of peptone water (Oxoid), Wellcotest broth, and urine (see below).

**GEL DIFFUSION**

Sulphamethoxazole and trimethoprim were placed in doubling dilutions, singly or in combination (in a ratio of 20:1 w/w), into wells of assay plates seeded with indicator strains. These comprised 10 strains of *Staphylococcus aureus* sensitive to sulphamethoxazole (MIC less than 20 mg/l in DST) and trimethoprim (MIC less than 1 mg/l in DST), and 40 strains resistant to sulphamethoxazole (MIC more than 200 mg/l) and sensitive to trimethoprim. These indicator strains were collected from clinical material during 1975-77 and were considered to be epidemiologically distinct isolates. Zones of inhibition were measured using a Leelbrook microbiological zone reader after 20 hours' incubation of plates. At least four replicates for each concentration were tested against each organism. Synergy was assessed by the ability of sulphamethoxazole to decrease, by at least fourfold, the trimethoprim concentration necessary to obtain the same zone size. The proportion of sulphamethoxazole to trimethoprim, when in combination, in diffusion testing was always 20:1. When synergy occurred it was evident across a wide range of concentrations of the drugs.

**CALCULATION OF THYMIDINE REQUIREMENTS OF THYMIDINE-DEPENDENT MUTANTS AND THEIR GENERATION TIMES**

Three thymidine-dependent strains of *Escherichia coli* and two of *Staph. aureus* were monitored in Wellcotest broth, with the addition of various amounts of thymidine. Purified cultures of these organisms were stored at 4°C on the surface of BAB containing 5 mg thymidine/l. Colonies were emulsified in saline and then added to 100 ml of Wellcotest broth in 250-ml conical flasks to give a final concentration of about 10⁶ bacteria/ml. The flasks were incubated, with standard agitation, in a controlled environment produced by a Gallenkamp rotary incubator at 37°C, 100 rpm. The cultures were sampled at hourly intervals for six hours by the application of a diluted culture to the surface of BAB containing 5 mg thymidine/l. Viable counts were calculated after 20 hours' incubation of these plates. The doubling times were calculated from the logarithmic phase of growth. A number of colonies were always picked from the viable counts after six hours' incubation to test for the presence of bacteria no longer requiring thymidine. No such revertants were found.

**BEHAVIOUR OF ORGANISMS IN URINE**

Urine was obtained from patients during the course of 'routine' investigations and was classified as either non-infected (containing less than 10⁸ bacteria/ml and less than 30 pus cells/ml) or infected (containing more than 10⁸ bacteria/ml and more than 100 pus cells/ml). These urine samples had been stored at 4°C for one to two days, were then centrifuged at 3000 g for 20 minutes to remove coarse debris, filtered through 0.45 mµ Millipore filters, and checked for sterility. Each was then tested for the presence of antibacterial agents by the application of 0.2 ml aliquots to wells cut in plates that had been seeded with a fully sensitive strain of *E. coli*. Those urines that contained any evidence of antibacterial effect were discarded.

Two types of experiment were performed on the urine. One was the addition of strains of *E. coli* that required thymidine; this was done in order to assay biologically the amount of free thymidine in urine. In these experiments, the urine was inoculated with a washed suspension of thymidine-dependent bacteria to a final density of about 10⁹/ml, and the artificially infected urine was incubated at 37°C with standard agitation (100 rpm). Viable counts were performed hourly for six hours.

The second type of experiment was the addition of sulphamethoxazole, trimethoprim, or the mixture (ratio 1:1 w/w, see below) to filtered, infected urine together with a suspension of one of three 'normal' strains of *E. coli* (obtained from clinical material). The effect of these agents was monitored as above. These three strains of *E. coli* were sensitive to the sulphamethoxazole (MIC less than 20 mg/l) and trimethoprim (MIC less than 1 mg/l), and each showed marked synergy with the mixture (ratio 20:1 w/w) in thymidine-free agar. The concentration of antibacterial substances was selected to represent active levels commonly found in urine.
Effect of thymidine on activity of trimethoprim and sulphamethoxazole

after therapeutic doses (Rieder et al., 1974). Thus, the final concentration of both sulphamethoxazole and trimethoprim was 100 mg/l, either singly or in combination.

THYMIDINE-DEPENDENT STRAINS
Three thymidine-dependent strains of E. coli isolated from urinary infections were kindly supplied by Dr R. Maskell, and two thymidine-dependent strains of Staph. aureus were kindly supplied by Mr D. Banner.

DRUGS
Trimethoprim was obtained from Burroughs Wellcome, sulphamethoxazole from Roche, epicillin from E. R. Squibb, and thymidine and other bases from Koch-Light Laboratories (puriss grade).

Results

PROPERTIES OF THYMIDINE-REQUIRING MUTANTS
The three strains of E. coli and two of Staph. aureus were confirmed as requiring thymidine for growth by the incorporation of test substances into wells but other nucleic acid bases (guanine, cytosine, adenine, or uracil) could not support growth. Thymine could support the growth of E. coli strains but not that of Staph. aureus. This was to be expected as this organism can take up thymidine but not thymine. In view of this, and the observation that thymidine could support growth at lower levels than could thymine, subsequent experiments were performed using thymidine. The incorporation of various amounts of thymidine into solid media (Wellcottest or DST), without the addition of lysed blood, produced normal colonial growth when levels of thymidine between 1 and 5 mg/l were reached. Above 5 mg/l there was no further increase in colony size. At lower levels of thymidine the colonies became smaller, and at levels of 0·1 mg/l or less no growth was apparent after 20 hours’ incubation at 37°C.

The precise minimum requirement of thymidine was obtained for each of these strains by the calculation of the effect of various levels of thymidine on the mean generation time. Levels greater than 5·0 mg/l did not decrease significantly the doubling time but were sometimes inhibitory (Fig. 1; Table 1).

Table 1  Effect of thymidine on generation times (min)* of three thymidine-requiring strains of E. coli and two of Staph. aureus

<table>
<thead>
<tr>
<th>Concentration of thymidine (mg/l) in Wellcottest broth</th>
<th>E. coli thy-1</th>
<th>E. coli thy-2</th>
<th>E. coli thy-3</th>
<th>Staph. aureus thy-1</th>
<th>Staph. aureus thy-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>D+</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>0·25</td>
<td>NT</td>
<td>D</td>
<td>42·3</td>
<td>39·9</td>
<td>NT</td>
</tr>
<tr>
<td>1·0</td>
<td>54·4</td>
<td>42·3</td>
<td>25·1</td>
<td>42·8</td>
<td>64·7</td>
</tr>
<tr>
<td>2·5</td>
<td>20·3</td>
<td>22·0</td>
<td>24·5</td>
<td>24·7</td>
<td>NT</td>
</tr>
<tr>
<td>5·0</td>
<td>23·1</td>
<td>23·0</td>
<td>23·7</td>
<td>28·8</td>
<td>30·2</td>
</tr>
<tr>
<td>10·0</td>
<td>22·9</td>
<td>32·1</td>
<td>21·0</td>
<td>26·2</td>
<td>28·5</td>
</tr>
<tr>
<td>50·0</td>
<td>26·1</td>
<td>36·6</td>
<td>21·8</td>
<td>25·4</td>
<td>28·9</td>
</tr>
</tbody>
</table>

*Calculated from the exponential phase of two experiments.
†denotes reduction in viable bacteria over six hours.
NT = not tested
Table 2 Effect of thymidine on MIC of sulphamethoxazole and trimethoprim, singly and in combination, for 10 indicator strains of Staph. aureus in various media

<table>
<thead>
<tr>
<th>Medium</th>
<th>MIC (mg/l) without thymidine (range, if variation between strains)</th>
<th>Lowest thymidine concentration to raise MIC (mg/l)</th>
<th>Range of fold increase in MIC at lowest thymidine level that raises MIC</th>
<th>MIC (mg/l) in presence of 5 mg/l thymidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wellcotest</td>
<td>0-25 T, 5-0 S</td>
<td>0-05</td>
<td>all &gt; 40</td>
<td>10 T, 200 S</td>
</tr>
<tr>
<td>(no added blood)</td>
<td>25-100 S</td>
<td>0-05</td>
<td>4- &gt; 10</td>
<td>1000 S</td>
</tr>
<tr>
<td>DST</td>
<td>0-05 T, 1-0 S</td>
<td>5-0</td>
<td>all &gt; 100</td>
<td>5 T, 100 S</td>
</tr>
<tr>
<td>(no added blood)</td>
<td>5-10 S</td>
<td>0-5</td>
<td>0-5</td>
<td>1000 S</td>
</tr>
<tr>
<td>DST</td>
<td>0-25-0.5 T</td>
<td>0-5</td>
<td>0-50</td>
<td>50 T</td>
</tr>
<tr>
<td>Wellcotest with</td>
<td>0-1 T, 2-0 S</td>
<td>---</td>
<td>---</td>
<td>0-1 T, 2-0 S</td>
</tr>
<tr>
<td>5% lysed horse</td>
<td>25-100 S</td>
<td>---</td>
<td>---</td>
<td>25-100 S</td>
</tr>
<tr>
<td>blood</td>
<td>0-5-1-0 T</td>
<td>---</td>
<td>---</td>
<td>0-5-1-0 T</td>
</tr>
<tr>
<td>DST with</td>
<td>0-05 T, 1-0 S</td>
<td>---</td>
<td>---</td>
<td>0-05 T, 1-0 S, 2-0 S T, 2-0 S</td>
</tr>
<tr>
<td>5% lysed horse</td>
<td>0-1 T, 2-0 S</td>
<td>---</td>
<td>---</td>
<td>10-25 S</td>
</tr>
<tr>
<td>blood</td>
<td>0-25-0.5 T</td>
<td>---</td>
<td>---</td>
<td>0-25-0.5 T</td>
</tr>
<tr>
<td>Wellcotest with</td>
<td>0-1 T, 2-0 S</td>
<td>0-1</td>
<td>0-25</td>
<td>2-5 T, 50 S</td>
</tr>
<tr>
<td>5% lysed human</td>
<td>10- &gt; 1000 S</td>
<td>0-5</td>
<td>0- &gt; 100</td>
<td>1000 S</td>
</tr>
<tr>
<td>blood</td>
<td>1-0 T</td>
<td>0-1</td>
<td>2-50</td>
<td>50 T</td>
</tr>
<tr>
<td>DST with</td>
<td>0-05 T, 1-0 S</td>
<td>0-5</td>
<td>0-5</td>
<td>2-5 T, 50 S</td>
</tr>
<tr>
<td>5% lysed human</td>
<td>10-25 S</td>
<td>0-5</td>
<td>0-5</td>
<td>1000 S</td>
</tr>
<tr>
<td>blood</td>
<td>0-5 T</td>
<td>0-5</td>
<td>0-2</td>
<td>50 T</td>
</tr>
</tbody>
</table>

*Levels of thymidine up to 5 mg/l had no effect on MIC. S = sulphamethoxazole; T = trimethoprim

**EFFECT OF THYMIDINE ON MIC OF TRIMETHOPRIM AND SULPHAMETHOXAZOLE**

The effect of various levels of thymidine on the MIC was examined in six media—DST or Wellcotest either alone or with the addition of 5% horse red cells or 5% human red cells. Ten standard strains of *Staph. aureus* were used throughout these experiments. These strains were fully sensitive to trimethoprim (MIC less than 1 mg/l) and sulphamethoxazole (MIC less than 20 mg/l) in DST agar.

The results are presented in Table 2. In both of the media containing no added red cells, the presence of low levels of thymidine caused a marked increase in the MIC of sulphamethoxazole, trimethoprim, and the combination. This effect was most marked with Wellcotest agar, in which as little as 0-05-0-1 mg thymidine/l affected the activity of the drugs. At thymidine levels of about 0-05-2-0 mg/l in Wellcotest agar, colonial appearance was often abnormal, the size becoming progressively larger at a particular drug concentration with increasing levels of thymidine. When thymidine was added (up to 5-0 mg/l) to either Wellcotest or DST containing 5% lysed horse red cells, there was no effect on the MIC for either trimethoprim, sulphamethoxazole, or the combination. Presumably the thymidine is inactivated rapidly and completely by thymidine phosphorylase present in horse red cells (Bushby, 1973). In contrast, in either Wellcotest or DST agar containing 5% human red cells, thymidine produced a marked increase in MIC comparable to that occurring without any added red cells (Table 2). This failure of human red cells to neutralise the antagonistic effect of thymidine is explicable by their lack of thymidine phosphorylase.

**EFFECT OF MEDIUM ON ACTIVITY OF SULPHAMETHOXAZOLE AND TRIMETHOPRIM TOWARDS SULPHONAMIDE-RESISTANT STAPHYLOCOCCI**

There have been conflicting views as to whether there is justification for the use of the combination, co-trimoxazole, against sulphonamide-resistant organisms. This uncertainty arises over the observations that some sulphonamide-resistant organisms do not show synergy towards this combination even under optimal conditions. Forty such strains of *Staph. aureus* (MIC greater than 200 mg/l in DST) were tested for synergy by MIC methodology in DST agar containing 5% (v/v) horse red cells. Under these optimum conditions, only six strains showed clearcut synergy, although many showed a very slight decrease in their requirement of sulphamethoxazole to produce equivalent inhibitory effect compared with trimethoprim alone. Experiments were then performed with the use of the above sulphonamide sensitive and resistant indicator strains in diffusion testing. Using DST and BAB
with or without lysed horse blood, the combination of trimethoprim and sulphanethoxazole was always synergistic against the 10 sensitive staphylococci. None of the 40 sulphonamide resistant strains showed synergy in diffusion in either medium. The apparent discrepancy between synergy, as shown by MIC methods and by diffusion testing, is unexplained, but the conflicting views as to whether sulphonamide resistant organisms do or do not show synergy with the combination may, in part, be accounted for by differences in methodology. For the treatment of lower urinary tract infections this debate would seem irrelevant (see below).

**EFFECT OF THYMIDINE ON ZONES OF INHIBITION OF SULPHAMETHOXAZOLE AND TRIMETHOPRIM OBTAINED IN DIFFUSION TESTING**

The effect of the incorporation of various levels of thymidine into agar in diffusion testing produced a progressive loss of the clarity of the zone, and, in general, the zone was completely lost at levels of thymidine between 1 and 5 mg/l in Wellcotest agar. Such an effect was difficult to quantify.

**GROWTH OF THYMIDINE-DEPENDENT STRAINS OF E. COLI IN URINE**

Three strains of thymidine-dependent *E. coli* were added to urine from patients with a urinary tract infection (16), or without such infection (3), and viable counts were obtained hourly for six hours. A control *E. coli* was included in each set of experiments so that each urine sample obtained was divided into four, and the behaviour of the thymidine-dependent strains was expressed relative to that of the control. The results for infected and non-infected urine were similar and have therefore been combined. Two of the thymidine-dependent strains (*E. coli* thy-1 and *E. coli* thy-2) failed to grow over six hours in any of the urines, usually being killed to various degrees. However, with the third strain (*E. coli* thy-3) growth often occurred, although not as well as that of the control (Fig. 2). The earlier finding that strains *E. coli* thy-1 and *E. coli* thy-2 required 2.5 mg thymidine/l for normal growth, but that *E. coli* thy-3 required only 1 mg/l, suggests that the amount of thymidine present in the urine is of the order of rather less than 1 mg/l. Since each of these thymidine-requiring strains has been isolated from patients with urinary tract infections, higher levels of thymidine appear to be present in infected tissues than were present in filtered urine. Nevertheless the presence of thymidine at levels of 0.25-1.0 mg/l could have important effects on the activity of sulphanethoxazole, trimethoprim, or the combination, since it has been found that such levels can affect the activity of these substances (see above).

**GROWTH OF STRAINS OF E. COLI IN INFECTED URINE IN PRESENCE OF SULPHAMETHOXAZOLE, TRIMETHOPRIM, OR THE COMBINATION**

Infected urine was obtained from 14 patients who had not received antibacterial agents, and a suspension of one of three 'normal' strains of *E. coli* was added to four 4-ml aliquots to give a final density of about 10^7 bacteria/ml. No antibacterial substance was added to one aliquot (control), 100 mg sulphanethoxazole/l was added to another, 100 mg trimethoprim/l to another, and 100 mg of sulphanethoxazole and 100 mg trimethoprim/l to the last. The growth of the organisms was monitored over six hours in a controlled environment. There were no marked differences between the behaviour of each of the bacteria, so the results were combined (Fig. 3). Growth in the control was comparable to that in urine containing sulphanethoxazole alone; that is, the rather low level of active sulphanethoxazole liberated from the combination appears to be insufficient to cause any inhibition of growth. This was rather surprising as the three strains of *E. coli* were inhibited in DST by about 10 mg/l of sulphanethoxazole, yet 100 mg/l of this substance in urine was non-inhibitory. This provides further evidence for the presence of antagonists in urine that are absent from synthetic media. The activity
of trimethoprim appeared identical with that of the combination with sulphonamide (Fig. 3). This was similar to the finding that, in urine obtained from healthy volunteers, there seemed to be no advantage in adding sulphonamide to trimethoprim, and there was certainly no synergistic effect detectable in the urine (Anderson et al., 1974). The activity of trimethoprim and sulphonamide in combination was found in the present study to cause a small reduction in viable bacteria over six hours that was slightly more pronounced than the activity found in volunteer urine (see Anderson et al. (1974)). This difference was presumably due to variations in materials. The activity of the mixture was, however, much less marked than that of a pencillin. Epicillin (an analogue of ampicillin) was added to eight infected urines to a final concentration of 100 mg/l and produced, over six hours, a reduction in viable bacteria of between $1.5 \times 10^4$ and $8.3 \times 10^5$, whereas trimethoprim and sulphonamide in combination produced a maximum reduction of only $4.2 \times 10^1$ (Fig. 3).

**Discussion**

The results presented here show how very low levels of thymidine in culture media can disrupt the activity of sulphonamide and trimethoprim. The presence of significant levels of thymidine are likely to occur in urine and would be expected to be important during therapy. Maskell *et al.* (1976) have already provided evidence for the presence of thymidine in urine by analysing urine from infected patients using ultraviolet absorption. Our finding that urine contains substances able to support the growth of one thymidine-requiring strain of *E. coli*, and that the synergy between sulphonamide and trimethoprim is disrupted in infected urine, is consistent with the presence of significant levels of thymidine in urine.

The presence of thymidine (and other such antagonists) has two important implications. One is the inference that if sensitivity testing is intended to reflect as closely as possible the clinical environment, then a certain amount of available thymidine should be present in media. Wellcotest agar contains 10 mg/l of bases other than thymine or thymidine, so a level of 10 mg/l thymidine might be an appropriate amount to incorporate into this medium to provide a realistic environment. It would certainly be sufficient to support the growth of thymidine-dependent bacteria. If it is desirable for free thymidine to be present in media, the addition of lysed horse red cells is obviously inappropriate.

The second implication of these findings is in the treatment of urinary tract infections with combinations of trimethoprim and sulphonamide. If our findings are applicable generally, then we suggest that the presence of the sulphonamide component of this combination has virtually no enhancing effect (that is, synergy) on the activity of trimethoprim. Greenwood and O'Grady (1976) have used a different approach in the simulation of urinary tract infections by the use of an automatic 'bladder' with bacteria suspended in Wellcotest broth. This has the advantage of mechanically resembling micturition, but infected urine will rarely be available in adequate amounts for use as a medium. However, Greenwood and O'Grady (1976) also considered that the effect of the trimethoprim and sulphonamide combination was dominated by the trimethoprim component. It may well be that in successful therapy with the combination co-trimoxazole all the antibacterial effect in urine is due to the trimethoprim component. If so,
Effect of thymidine on activity of trimethoprim and sulphamethoxazole

numerous patients have been exposed unnecessarily to subclinical levels of sulphonamides. A recent report of 13 cases of fatal marrow aplasia associated with the use of co-trimoxazole (Inman, 1977) increases the importance of this possibility. Furthermore, unnecessary exposure of bacteria to sulphamethoxazole has also occurred.

While we consider that the activity of sulphamethoxazole may well be inadequate in vivo, other sulphonamides are present in urine in sufficient amounts to be effective against sulphonamide-sensitive organisms. Sulphamethoxazole was the sulphonamide chosen to match trimethoprim on account of its pharmacokinetic properties; it is unfortunate that the active urinary level of this substance is so low, as little as 10 mg/l being present in the urine of some patients with impaired renal function (Rieder et al., 1974).

In 1974, Anderson et al. stated that 'there is obviously an urgent need for further clinical comparisons of these two agents (the combination and trimethoprim) in order to identify conditions for which the trimethoprim component should be given alone'. It is regrettable that trimethoprim is still not generally available so that such a comparison cannot be made.

The chief conclusions from this work furnish additional evidence for the lack of any advantage in combining sulphamethoxazole with trimethoprim for the treatment of lower urinary tract infections and suggest that thymine and thymidine-free agar may not give a realistic assessment of the activity in vivo of these drugs.

References


Effect of thymidine on activity of trimethoprim and sulphamethoxazole.

A Stokes and R W Lacey

*J Clin Pathol* 1978 31: 165-171
doi: 10.1136/jcp.31.2.165

Updated information and services can be found at:
http://jcp.bmj.com/content/31/2/165

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/